Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103662 · ClinicalTrials.gov registry record · Phase 3
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT00103662 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 302 participants.
The verdict
NCT00103662, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.
Interventions
- DRUG Granulocyte colony-stimulating factor plus plerixafor
- DRUG Granulocyte colony-stimulating factor plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103662
The ClinicalTrials.gov registry entry for NCT00103662 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Granulocyte colony-stimulating factor plus plerixafor is the first listed.
NCT00103662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103662 about?
NCT00103662 is a clinical study titled "Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients". The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous tran...
What is the current status of trial NCT00103662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2005-01. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00103662?
The interventions under investigation include: Granulocyte colony-stimulating factor plus plerixafor (DRUG), Granulocyte colony-stimulating factor plus placebo (DRUG).
Who is sponsoring clinical trial NCT00103662?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.